We are live on ! Find out more
BNTX icon

BioNTech

320 hedge funds and large institutions have $6.02B invested in BioNTech in 2022 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 103 increasing their positions, 84 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 17

23% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 84

21% more funds holding

Funds holding: 264320 (+56)

20% more capital invested

Capital invested by funds: $5B → $6.02B (+$1.01B)

1.07% more ownership

Funds ownership: 15.29%16.35% (+1.1%)

17% less call options, than puts

Call options by funds: $349M | Put options by funds: $421M

22% less funds holding in top 10

Funds holding in top 10: 97 (-2)

Holders
320
Holders Change
+56
Holders Change %
+21.21%
% of All Funds
5.14%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.11%
New
76
Increased
103
Reduced
84
Closed
17
Calls
$349M
Puts
$421M
Net Calls
-$71.2M
Net Calls Change
+$60.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$1.16B +$72.8M +473,051 +7%
Temasek Holdings
2
Temasek Holdings
Singapore
$658M
Primecap Management
3
Primecap Management
California
$627M -$3.27M -21,222 -0.5%
Flossbach Von Storch
4
Flossbach Von Storch
Germany
$493M -$12.6M -81,841 -2%
Artisan Partners
5
Artisan Partners
Wisconsin
$362M +$27.4M +177,787 +8%
Capital World Investors
6
Capital World Investors
California
$311M +$68.3M +443,586 +27%
BlackRock
7
BlackRock
New York
$309M +$84M +545,623 +36%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$118M -$72.6M -472,031 -38%
Coatue Management
9
Coatue Management
New York
$92.9M +$30.3M +196,641 +47%
Deutsche Bank
10
Deutsche Bank
Germany
$91.4M -$6.11M -39,727 -6%
UBS AM
11
UBS AM
Illinois
$72.2M +$21.7M +140,865 +41%
GGHC
12
Gilder Gagnon Howe & Co
New York
$68.9M +$6.23M +40,478 +10%
Morgan Stanley
13
Morgan Stanley
New York
$67.4M +$16.7M +108,244 +32%
SEI Investments
14
SEI Investments
Pennsylvania
$58.4M +$11.5M +75,027 +24%
Marshall Wace
15
Marshall Wace
United Kingdom
$57.5M +$36.6M +237,709 +164%
First Trust Advisors
16
First Trust Advisors
Illinois
$52.9M +$11.8M +76,552 +28%
Renaissance Technologies
17
Renaissance Technologies
New York
$49.8M +$51M +331,484 New
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$46.9M +$33.4M +217,092 +228%
N
19
Nuveen
North Carolina
$46.5M +$15.5M +100,887 +48%
AAM
20
Abeille Asset Management
France
$46M +$727K +4,726 New
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$45.5M +$29.6M +192,600 +175%
BCAM
22
Boston Common Asset Management
Massachusetts
$40.5M -$1.55M -10,084 -4%
QOP
23
Quinn Opportunity Partners
Virginia
$39.4M -$1.23M -7,986 -3%
DekaBank Deutsche Girozentrale
24
DekaBank Deutsche Girozentrale
Germany
$38.9M -$4.95M -32,159 -11%
Mitsubishi UFJ Trust & Banking
25
Mitsubishi UFJ Trust & Banking
Japan
$37.1M -$469K -3,050 -1%

BNTX Hedge Fund Activity: Q4 2022 in Review

320 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2022, worth a combined $6.02B — up 20% from $5B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new BNTX positions and 17 closed out — a net gain of 59 holders — while 103 added to existing stakes and 84 trimmed.

The largest buyer was BlackRock, adding an estimated $84M. The largest seller was Fosun International, exiting entirely with an estimated $103M sold.

  • 320 institutional investors held BioNTech (BNTX) as of Q4 2022, up from 264 in Q3 2022.
  • Funds reported $6.02B of BioNTech stock for Q4 2022, up 20% quarter-over-quarter.
  • 76 funds opened new BioNTech positions in Q4 2022 and 17 closed out, a net change of +59 holders.
  • The largest BioNTech buyer in Q4 2022 was BlackRock, an estimated $84M added.
  • The largest BioNTech seller in Q4 2022 was Fosun International, an estimated $103M sold.

Based on aggregated 13F filings for Q4 2022.